Skip to main content

Table 1 Baseline characteristics of the study subjects

From: Intralymphatic immunotherapy with tyrosine-adsorbed allergens: a double-blind, placebo-controlled trial

 

Cohort for testing procedural safety

 

Cohort for testing treatment efficacy (at 4 months after ILAIT)

 

Cohort for testing treatment efficacy (at 1 year after ILAIT)

 
 

All subjects(n = 32)

Active group (n = 19)

Control group (n = 13)

P-value

All subjects (n = 30)

Active group (n = 17)

Control group (n = 13)

P-value

All subjects (n = 22)

Active group (n = 13)

Control group (n = 9)

P-value

Age, year

34.2 ± 9.5

32.4 ± 11.1

36.9 ± 5.9

0.037

34.9 ± 9.3

33.4 ± 11.2

36.9 ± 5.9

0.079

36.5 ± 9.7

35.2 ± 11.8

38.4 ± 5.7

0.186

No. of Female

19 (59.4)

11 (57.9)

8 (61.5)

0.565

18 (60.0)

9 (52.9)

8 (61.5)

0.410

13 (59.1)

7 (53.8)

6 (66.7)

0.439

Symptom duration, years

14.5 ± 9.5

15.8 ± 8.7

12.8 ± 10.6

0.648

14.2 ± 9.6

15.4 ± 9.0

12.8 ± 10.6

0.674

14.5 ± 10.0

13.6 ± 10.3

15.4 ± 10.3

0.645

Comorbid allergic diseases

 Asthma

19 (59.4)

11 (57.9)

8 (61.5)

0.470

18 (60.0)

10 (58.8)

8 (61.5)

0.508

13 (59.0%)

7 (53.8)

6 (66.7)

0.436

 Urticaria

7 (21.9)

6 (31.6)

1 (7.7)

0.186

6 (20.0)

5 (29.4)

1 (7.7)

0.240

4 (18.2)

4 (30.8)

0 (0.0)

0.184

 Food allergy

6 (18.8)

5 (26.3)

1 (7.7)

0.294

6 (20.0)

5 (29.4)

1 (7.7)

0.240

5 (22.7)

4 (30.8)

1 (11.1)

0.423

 Drug allergy

5 (15.6)

3 (15.8)

2 (15.4)

0.660

5 (16.6)

3 (17.7)

2 (15.4)

0.657

4 (18.1)

3 (23.1)

1 (11.1)

0.652

 Atopic dermatitis

4 (12.5)

2 (10.5)

2 (15.4)

0.542

4 (13.3)

2 (11.8)

2 (15.4)

0.591

3 (13.6)

2 (15.4)

1 (11.1)

0.642

 Family history of allergic diseases

21 (65.6)

11 (57.9)

10 (76.9)

0.283

20 (66.7)

10 (58.8)

10 (76.9)

0.259

15 (68.2)

8 (61.5)

7 (77.8)

0.372

Target allergen

 Dermatophagoides farinae

22 (68.8)

13 (68.4)

9 (69.2)

0.636

20 (66.7)

11 (64.7)

9 (69.2)

0.554

15 (68.2)

8 (61.5)

7 (77.8)

0.372

 D. pteronyssinus

21 (65.6)

13 (68.4)

8 (61.5)

0.487

19 (63.3)

11 (64.7)

8 (61.5)

0.579

14 (63.6)

8 (61.5)

6 (66.7)

0.584

 Cat

19 (59.4)

10 (52.6)

9 (69.2)

0.285

18 (60.0)

9 (52.9)

9 (69.2)

0.301

12 (54.5)

7 (53.8)

5 (55.6)

0.639

 Dog

8 (25.0)

5 (26.3)

3 (23.1)

0.587

7 (23.3)

4 (23.5)

3 (23.1)

0.660

6 (27.3)

3 (23.1)

3 (33.3)

0.477

  1. Data are shown as the means ± standard deviations (SDs) or frequencies (%). ILAIT intralymphatic allergen-specific immunotherapy